Lataa...
Beyond DNA repair: the novel immunological potential of PARP inhibitors
Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work...
Tallennettuna:
| Julkaisussa: | Mol Cell Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6512907/ https://ncbi.nlm.nih.gov/pubmed/31131303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2019.1585170 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|